Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Ardellix Fourth Quarter 2025 Earnings Conference. All participants will be in a listen-only mode. I would now like to turn the conference over to Kaitlyn Lowy, Vice President of Corporate Communications and Investor Relations. Kaitlyn, you may begin. Thank you. Good afternoon and welcome to our fourth quarter and full year 2025 financial results call. During this call, we will refer to the press release issued earlier today, which is available on the investor section of the company's website at ardellis.com. Please note that we are also including a slide presentation to accompany today's remarks. You can view the material by accessing the webcast version of today's call on the investor section of ardellis.com. During this call, we will be making forward-looking statements that are subject to risks and uncertainties. Our actual results may differ significantly from those described. We encourage you to review the risk factors in our most recent annual report on Form 10-K that will be filed today. It can be found on our website at ardellix.com. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change. Our President and CEO, Mike Robb, will begin today's call with opening remarks filed by Eric Foster, Chief Commercial Officer, who will provide an update on the performance of Isdrella and Expoza. Dr. Laura Williams, our Chief Patient Officer and Interim Chief Medical Officer, will share an update on our recently announced development program before our Chief Financial Officer, Sue Hohenleitner, reviews the company's financial performance. We will then open the call to questions. With that, let me pass the call over to Mike. Thank you, Kaitlin, and good afternoon, e...